Please assess the completion status of the following clinical trial:

Trial Title: Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent or progressive Non-Small Cell Lung Cancer stage IV or IIIB patients.~* Positive EGFR Mutation.~* No previous systemic anticancer therapy.~* Measurable lesion according to RECIST with at least one measurable lesion not previously irradiated, unless disease progression has been documented at that site.~* Provision of written informed consent.~Exclusion Criteria:~* Experience of Anti-EGFR(the epidermal growth factor receptor) Monoclonal Antibody or small molecular compounds therapy such as gefitinib, erlotinib or Cetuximab.~* Evidence of clinically active Interstitial Lung Diseases (Patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded).~* Known severe hypersensitivity to icotinib or any of the excipients of this product.~* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Icotinib (Type: EXPERIMENTAL): Icotinib 125mg is administered orally three times per day.
- Chemotherapy (Type: ACTIVE_COMPARATOR): Patients in this arm will receive pemetrexed/cisplatin for 4 cycles, of who don't progress will receive maintenance treatment with pemetrexed.

Based on this trial design, predict the completion outcome and termination type (if applicable).